Matt Henriksen

Today's show is brought to you by Vanguard.

To all the financial advisors listening, let's talk bonds for a minute.

Capturing value and fixed income is not easy.

Bond markets are massive, murky, and let's be real, lots of firms throw a couple flashy funds your way and call it a day.

But not Vanguard.

At Vanguard, institutional quality isn't a tagline.

It's a commitment to your clients.

We're talking top-grade products across the board of over 80 bond funds.

actively managed by a 200-person global squad of sector specialists, analysts, and traders.

These folks live and breathe fixed income.

So if you're looking to give your clients consistent results year in and year out, go see the record for yourself at Vanguard.com slash audio.

That's Vanguard.com slash audio.

All investing is subject to risk.

Vanguard Marketing Corporation Distributor.

Welcome to another episode of the Vanguards of Healthcare series.

My name is Matt Henriksen, the medical technology analyst at Bloomberg Intelligence, which is the in-house equity research platform of Bloomberg LP.

We are pleased to have with us today Mark Tolan, chairman of AVS Pulse, a privately held medical device company that is developing new innovation in intravascular lithotripsy, or IVL for short.

Mark, thank you for joining us today.

Perfect.

And, you know, I was just going to say you've been here about a year and a half ago.